 Glaukos Corp NYSE: GKOS shares are trading higher by 1.87 to 49.00 Wednesday morning after the company announced topline data for both Phase 3 pivotal trials of iDose TR that successfully achieved its pre-specified primary efficacy endpoints through 3 months in both Phase 3 trials and demonstrated ex 